Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.

PloS one - 1 Jan 2012

Chen Brenden, Tardell Christine, Higgins Brian, Packman Kathryn, Boylan John F, Niu Huifeng

Abstract excerpt

Cross-feedback activation of MAPK and AKT pathways is implicated as a resistance mechanism for cancer therapeutic agents targeting either RAF/MEK or PI3K/AKT/mTOR. It is thus important to have a better understanding of the molecular resistance mechanisms to improve patient survival benefit from these agents. Here we show that BRAFV600E is a negative regulator of the AKT pathway. Expression of BRAFV600E in NIH3T3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Activation
Share to Extracellular Signal-Regulated MAP Kinases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Mitogen-Activated Protein Kinase Kinases

Share to NIH 3T3 Cells

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to Sirolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 22880048
DOI: 10.1371/journal.pone.0042598
PMCID: PMC3411810

Genes

BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.PMID 22880048Read ↗

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.Semantic proximity Read ↗

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Semantic proximity Read ↗

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Semantic proximity Read ↗

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.Semantic proximity Read ↗

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTENSemantic proximity Read ↗

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studiesSemantic proximity Read ↗

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.Semantic proximity Read ↗

RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition.Semantic proximity Read ↗

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.